Skip to main content

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Active, not recruiting · Phase 3 · NCT06141486

Conditions: Multiple Sclerosis

At a glance

Research payments reported, 2025
$4.9M
U.S. investigators named
92
Sites paid
96
Planned or actual enrollment
943

About the trial

Sponsor
Sanofi
Tested
Frexalimab (drug), Placebo (drug), MRI contrast-enhancing agents (drug)
Dates
Started 2023-12-27; completion 2028-03-24
Results posted
Not yet

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first …

From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Genzyme Corporation reported $4.9M in research payments for this study in 2025 (349 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.